Hybrid clinical trials blend traditional in-person site visits with remote or decentralized elements like telehealth check-ins, wearable sensors, and direct-to-patient drug shipments. Rather than forcing every participant to travel to a research center for every procedure, a hybrid trial picks and chooses which activities genuinely require an in-person presence and which can happen at home. The model gained serious traction during the pandemic and has since become the most commonly discussed path toward making clinical research less burdensome for the people it depends on.
What Makes a Trial “Hybrid”
A fully traditional trial requires participants to visit a clinical site for every study activity: dosing, blood draws, physical exams, questionnaires, safety monitoring. A fully decentralized trial moves all of those activities off-site. A hybrid trial sits in between, using a mix of on-site and remote methods tailored to the needs of the study and the participants. Remote methods can include telehealth visits, electronic collection of patient-reported outcomes, connected sensors or wearable devices, and home delivery of study medications.1NIH Pragmatic Trials Collaboratory. Decentralized Pragmatic Clinical Trials: What Is a Decentralized Trial? Some teams describe this as a “click and mortar” approach, where a participant might enroll online and complete regular check-ins via an app, but still comes to a clinic for certain physical procedures or lab work.
The exact split between in-person and remote varies enormously from trial to trial. In oncology, where patients need infusions and close monitoring, hybrid trials tend to keep treatment visits on-site while shifting follow-up surveys, symptom tracking, and some safety reporting to digital tools. In lower-risk settings like behavioral health or smoking cessation studies, the balance can tip further toward remote activities. There is no single template. The design depends on the drug’s safety profile, the regulatory environment, what endpoints are being measured, and the practical realities of the patient population.
Why the Model Gained Ground
Clinical trials have long struggled with slow recruitment, high dropout rates, and participant populations that do not reflect the broader community. The COVID-19 pandemic forced the industry to figure out remote alternatives almost overnight. Decentralized trial methods and digital health tools had been discussed for years, but the pandemic proved they could work at scale.2PubMed. Data-Driven and Technology-Enabled Trial Innovations Toward Decentralization of Clinical Trials: Opportunities and Considerations
Even as pandemic restrictions faded, many of the reasons for hybrid designs remained. Travel to research centers is a real barrier for participants, especially those in rural areas, those with disabilities, and those who cannot easily take time off work. One trial team estimated that under a fully in-person design, coordinators would have needed to cover a four-county region spanning roughly 145 square miles. Shifting to remote methods eliminated that travel burden for both participants and research staff.3PubMed Central. From hybrid to fully remote clinical trial amidst the COVID-19 pandemic: Strategies to promote recruitment, retention, and engagement in a randomized mHealth trial European regulators have echoed this, identifying reduced participation burden as a key opportunity of decentralized and hybrid approaches.4Utrecht University. Opportunities and Challenges for Decentralized Clinical Trials: European Regulators’ Perspective
Recruiting Faster and Reaching More People
One of the most tangible benefits of hybrid designs is their effect on recruitment speed. A phase I/IIa trial for actinic keratosis used an online recruitment flow that combined social media advertising with virtual eligibility screening before in-clinic enrollment. The team enrolled 60 patients in 53 days, averaging more than one patient per day per site. Compared to published benchmarks, recruitment efficiency was roughly nine times higher than average.5Contemporary Clinical Trials Communications. Accelerating patient recruitment using social media: Early adopter experience from a good clinical practice-monitored randomized controlled phase I/IIa clinical trial on actinic keratosis
A trial engaging adolescents compared three recruitment strategies head to head: traditional in-clinic outreach, fully digital campaigns, and a targeted hybrid approach that used letters and text messages. The hybrid method had the shortest active recruitment timeline at about a year and a half, yet it brought in the most participants of any single strategy, averaging 19 per quarter.6npj Digital Medicine. Representation is power: traditional, hybrid, and digital recruitment results from a non-randomized clinical trial engaging adolescents Speed alone is useful, but hybrid trials are also attracting attention for who they recruit, not just how quickly.
Improving Diversity in Enrollment
Clinical trials have historically enrolled participant pools that skew white, affluent, and geographically close to academic medical centers. The same adolescent trial that compared recruitment strategies found that the targeted hybrid approach using letters and texts enrolled the highest proportion of participants from groups historically underrepresented in research: about 88%, compared with roughly 49% for traditional methods and 32% for fully digital recruitment.7npj Digital Medicine. Representation is power: traditional, hybrid, and digital recruitment results from a non-randomized clinical trial engaging adolescents That gap is striking. Purely digital outreach, despite casting a wide net, pulled in the least diverse group. The hybrid strategy, which combined a personal touch with the convenience of remote participation, reached communities that traditional and digital approaches each missed on their own.
This finding is particularly relevant given that regulators and funders are increasingly demanding that trial populations reflect the communities who will eventually use the treatments being studied. A hybrid model does not automatically solve the diversity problem, but the early evidence suggests it can move the needle in the right direction when the outreach is designed with underrepresented communities specifically in mind.
Retention and Adherence
Getting people enrolled is one thing; keeping them in the study is another. There has been reasonable concern that remote activities might make participants feel less connected and more likely to drop out. A smoking cessation trial compared hybrid and fully remote methods and found no significant differences in visit attendance, dropout rates, or recruitment pace between the two groups.8PubMed Central. Comparison of remote to hybrid methods on recruitment and retention rates in a smoking cessation trial That result is reassuring, if preliminary. It suggests that removing some in-person visits does not necessarily make participants less engaged, at least in populations comfortable with remote tools.
Wearables and Remote Data Collection
Wearable devices are one of the technologies that make hybrid trials practical. Smartwatches, biosensors, wearable patches, and continuous glucose monitors can track heart rate, physical activity, sleep quality, blood oxygen, and other physiological signals around the clock, generating a density of data that periodic clinic visits could never match.9PubMed Central. Wearable technologies in clinical trials for drug development: trends and emerging opportunities A review catalogued more than 1,000 interventional trials registered between 2001 and 2025 that incorporated wearable-derived data into their study protocols, showing how rapidly this technology has been adopted.
The question, of course, is whether data collected remotely through wearables is as reliable as data collected on-site. A hybrid decentralized trial in South Korea tested this directly. In the decentralized arm, participants self-administered their doses at home while wearing monitoring devices. The wearable records showed only about 2% missing data, with high agreement between the device logs and participants’ own paper records. The decentralized arm actually achieved 100% dosing adherence, while one participant in the conventional arm missed a dose at the clinic. Adverse event detection was comparable across both arms.10PubMed Central. Pioneering a Hybrid Decentralized Clinical Trial in South Korea: Assessing Feasibility, Data Integrity, and Participant Perceptions One study does not settle the question definitively, but results like these make a credible case that remote monitoring can hold up.
Getting Study Drugs to Participants’ Homes
If a trial moves certain visits out of the clinic, it often needs a way to get the investigational drug to the participant’s door. This is more complicated than shipping a consumer product. Study medications require temperature monitoring, chain-of-custody documentation, and sometimes special handling. The Trials@Home RADIAL proof-of-concept trial in Europe tested direct-to-participant delivery and completed 68 shipments with a 94% success rate. The four failed shipments were caused by a mix of the participant not being home, temperature excursions during transit, defective monitoring equipment, and a courier losing the package.11PubMed Central. The Supply of Investigational Medicinal Product and Management of Study Materials for Decentralized Participants-Insights from the Trials@Home RADIAL Proof-of-Concept Trial The lesson: direct-to-patient drug delivery works in principle, but it demands meticulous planning and clear agreements with courier vendors about what happens when something goes wrong.
In oncology, where many drugs are administered intravenously and require supervision, direct shipment tends to be reserved for oral medications with manageable safety profiles. One initiative at the University of North Carolina evaluated each drug’s suitability for home delivery based on its safety profile, administration complexity, monitoring needs, and shipping requirements before deciding whether it could leave the investigational pharmacy.12PubMed Central. Building HOPE: operationalizing hybrid decentralized oncology clinical trials with community providers beyond traditional healthcare system networks Not every drug can or should be shipped home. This is one of the design decisions that makes “hybrid” a more practical label than “fully decentralized” for many therapeutic areas.
What Regulators Expect
Both the U.S. Food and Drug Administration and the European Medicines Agency have published guidance on decentralized trial elements. The two agencies share common ground in emphasizing two priorities: participant safety and data integrity.13PubMed Central. The landscape of decentralized clinical trials (DCTs): focusing on the FDA and EMA guidance Neither agency says you cannot run a hybrid trial; they say you need to demonstrate that whatever happens remotely maintains the same safety oversight and data quality standards as what happens in the clinic.
European regulators interviewed about decentralized trials expressed concern about maintaining investigator oversight when physical exams and face-to-face contact are limited. Their recommended path forward: hybrid trials that preserve on-site elements where they matter most, rather than pushing everything remote at once.14Utrecht University. Opportunities and Challenges for Decentralized Clinical Trials: European Regulators’ Perspective This is the practical reality behind the hybrid model. It is not a halfway compromise born of timidity. It is a deliberate design philosophy that preserves in-person contact where clinical judgment or hands-on assessment is irreplaceable, and shifts the rest to wherever is most convenient for the participant.
How Research Sites Feel About the Shift
For all the enthusiasm about patient-centered design, the people running trials at research sites have a more mixed perspective. A survey found that about half of site staff view decentralized approaches as more burdensome than traditional ones. The pattern is interesting: operational and managerial tasks were generally seen as easier when handled remotely, while clinical procedures and anything requiring direct patient interaction were perceived as harder under a decentralized model.15PubMed. Quantifying Site Burden to Optimize Protocol Performance Sites also worry about data security, the physical safety of employees in nontraditional settings, and whether they will receive adequate technical support for new digital tools.16Mayo Clinic Proceedings: Digital Health. Comparison of Participant and Site Perceptions of Decentralized Clinical Trials in the USA
This disconnect between participant enthusiasm and site ambivalence is one of the underappreciated friction points in hybrid trial adoption. A trial design that is wonderful for the patient but overwhelming for the coordinator is not sustainable. Getting the balance right means investing in training, robust technology platforms, and workflows that actually reduce site workload for the activities moved off-site rather than simply relocating burden from the participant to the staff.
The Digital Divide Problem
There is an uncomfortable tension at the heart of the hybrid model. The same digital tools that make participation easier for some people can exclude others. A systematic review of digital and decentralized mental health trials found that digital literacy was rarely assessed. Only a handful of trials even checked whether participants had the skills to use the required technology, and only one study actually built in support mechanisms like instructions for checking internet connectivity.17PLOS Digital Health. Who gets included? Equity in digital and decentralised mental health and neurodevelopmental trials: A systematic review
A review focused on HIV research echoed the concern: while technology access is growing rapidly, consistent access remains limited for many people due to cost and unreliable infrastructure. If digital trials collectively exclude people with limited technology access, the evidence base itself becomes biased. Treatments found effective in tech-savvy populations may be scaled up without ever being tested in the communities that might benefit most.18Epidemiologic Reviews. Addressing Health Inequities in Digital Clinical Trials: A Review of Challenges and Solutions From the Field of HIV Research The idea of “digital navigators,” clinic staff trained to provide hands-on technical help to participants, has been floated as one solution. But for now, most trials have not built this kind of support into their protocols.
Oncology and Rare Diseases
Oncology is one of the therapeutic areas where hybrid designs face the steepest practical challenges and perhaps the greatest potential payoff. Cancer patients often need infusions, imaging, and close monitoring for serious adverse events, all of which are hard to do remotely. The UNC Lineberger Comprehensive Cancer Center’s HOPE initiative tackled this by partnering with nine community hospitals that had no formal research network agreements. The team convened 120 stakeholders including providers, nurses, pharmacists, and patient advocates to co-develop workflows for hybrid decentralized cancer trials. The workflows covered communication protocols, adverse event management, and literacy-sensitive patient materials, all designed to fit within existing clinical routines without requiring community providers to become formally engaged in research.19PubMed Central. Building HOPE: operationalizing hybrid decentralized oncology clinical trials with community providers beyond traditional healthcare system networks Under current regulatory guidance, local healthcare providers who perform tasks within their normal clinical qualifications are not considered research-engaged, which simplifies the regulatory paperwork considerably.
Rare diseases present a different but equally compelling case. Patients with ultra-rare conditions are scattered geographically, and asking them all to travel to a single center may be impossible. A trial for CLN3 disease, an ultra-rare lysosomal storage disorder, established 18 “spoke” sites near individual participants’ homes for 19 enrolled patients. Only about a third of the spoke-site investigators had any prior clinical trial experience, which meant the central team had to invest heavily in startup training and ongoing oversight. Despite those hurdles, all but one participant completed every study visit, and none were missed because of travel requirements.20PubMed. A novel, hybrid, single- and multi-site clinical trial design for CLN3 disease, an ultra-rare lysosomal storage disorder For rare disease research, the hybrid hub-and-spoke model may be the only way to run a trial at all.
The Financial Case
Running a clinical trial is expensive, and failed or slow trials are the most expensive of all. An economic modeling study estimated that applying decentralized methods to both Phase II and Phase III trials could increase the value of a drug development program by about $20 million per drug entering Phase II, with a seven-fold return on investment.21PubMed Central. Assessing the Financial Value of Decentralized Clinical Trials Most of that value comes from faster enrollment timelines and lower dropout rates, which reduce the time a drug spends in development and improve the probability of getting usable results. Whether those modeled savings translate cleanly into real-world budgets is still being tested, but the directional case is strong enough that sponsors are investing.
The Other “Hybrid” in Clinical Research
If you search for “hybrid clinical trials” in academic literature, you will encounter a second, unrelated use of the term: effectiveness-implementation hybrid designs. These are not about mixing in-person and remote visits. Instead, they blend two research goals. A traditional trial tests whether a treatment works. An implementation study asks how to get a treatment that already works into routine clinical practice. A hybrid design does both at once.22PubMed Central. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact
There are three types. A Type 1 hybrid primarily tests whether a treatment is effective while observing how easy it would be to implement. A Type 2 hybrid gives equal weight to both questions, testing the treatment’s effectiveness and the implementation strategy side by side. A Type 3 hybrid focuses mainly on the implementation strategy while keeping one eye on whether the treatment still performs as expected.23PubMed Central. An introduction to effectiveness-implementation hybrid designs An example of this in practice is the SIMPRO consortium, which is testing an electronic symptom management program for cancer patients while simultaneously studying how to integrate it into multiple health systems’ electronic health records. The primary outcome is whether the program reduces emergency department visits, but the trial is also generating evidence on the practicalities of deploying the software across six different institutions.
The two meanings of “hybrid” sometimes overlap. A hybrid decentralized oncology trial that also tracks how well its workflows integrate into community hospitals is doing implementation research whether it names it that way or not. But the terminology matters when you are reading papers or talking to a research team, because a “Type 2 hybrid” and a “hybrid DCT” are fundamentally different designs solving different problems.
Where the Model Has Room to Grow
Hybrid trials are still evolving faster than the infrastructure around them. Most existing workflows have been developed trial by trial, with each team reinventing logistics for drug shipping, remote consent, wearable data management, and community provider coordination. A systems-thinking framework has been proposed to evaluate how decentralized solutions affect all stakeholders through iterative assessment of pain points, with the core recommendation being that solutions need to be customized to each trial rather than applied as a one-size-fits-all package.24Therapeutic Innovation & Regulatory Science. Applying Systems Thinking to Inform Decentralized Clinical Trial Planning and Deployment That is honest advice, but it also means the field lacks standardized playbooks. Every new hybrid trial faces a learning curve that a more mature model would have flattened.
Hybrid monitoring systems are also being tested in investigator-sponsored trials in cancer, where budgets are smaller and infrastructure is thinner than in industry-sponsored work. One evaluation found that a hybrid risk-adapted monitoring approach was feasible and could detect both major and minor protocol issues across multiple centers.25PubMed. Feasibility of a Hybrid Risk-Adapted Monitoring System in Investigator-Sponsored Trials in Cancer The fact that academic investigators are adopting these methods suggests that hybrid designs are not just a luxury for well-funded pharmaceutical companies but a practical tool for any research team willing to invest in the upfront design work.